A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer

BACKGROUND: MLN0128 is a first-in-class, dual mTOR inhibitor with potential to outperform standard rapalogs through inhibition of TORC1 and TORC2. This phase II study was designed to assess antitumor activity of MLN0128 in metastatic castration-resistant prostate cancer (mCRPC). METHODS: Eligible pa...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Invest New Drugs
Hlavní autoři: Graham, Laura, Banda, Kalyan, Torres, Alba, Carver, Brett S., Chen, Yu, Pisano, Katie, Shelkey, Greg, Curley, Tracy, Scher, Howard I., Lotan, Tamara L., Hsieh, Andrew C., Rathkopf, Dana E.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2018
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6050986/
https://ncbi.nlm.nih.gov/pubmed/29508246
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-018-0578-9
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky